2TK Stock Chart & Stats
€3.20
€0.04(1.27%)
At close: 4:00 PM EDT
€3.20
€0.04(1.27%)
Day’s Range― - ―
52-Week Range€1.17 - €3.70
Previous CloseN/A
Volume0.00
Average Volume (3M)5.00
Market Cap
€226.22M
Enterprise Value€291.43
Total Cash (Recent Filing)€111.09M
Total Debt (Recent Filing)€555.00K
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding77,187,820
10 Day Avg. Volume15
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.23Price Target Upside157.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA very low debt load provides durable financial flexibility: it reduces bankruptcy and interest burden risk, preserves capacity to access non-dilutive financing, and gives management room to fund clinical milestones or partner negotiations without immediate pressure from creditors.
Authorized Share IncreaseExpanding authorized shares materially improves the company's long-term financing and strategic options: it enables equity raises, partnering transactions, or stock-based deals to fund costly clinical development and potential inorganic growth without needing charter amendments later.
Focused Clinical PipelineConcentrated R&D on a CD40L-targeting monoclonal antibody addresses a clear, structural unmet need in transplant immunology. A focused strategy can streamline development, attract specialized partners, and create durable competitive value if clinical efficacy and regulatory progress are demonstrated.
Bears Say
No RevenuePersistent zero revenue means the business model remains pre-commercial and reliant on capital markets. Over the medium term this elevates dilution and execution risk: without milestone partnerships or product sales, the firm must secure external funding to advance trials and reach commercialization.
Large Cash BurnConsistent negative operating and free cash flow depletes reserves and forces repeated financing. Structural cash burn increases dependence on equity or partnerships, pressures management to prioritize near-term funding over long-term optionality, and raises the risk of program delays if capital access tightens.
Dilution & Equity Erosion RiskWhile authorized-share expansion aids financing, it concretely raises long-term dilution risk given ongoing losses and negative equity trends. Structural equity erosion can reduce existing shareholders' claim on future upside and complicate incentives unless offset by meaningful clinical or partnership value creation.
Eledon Pharmaceuticals News
2TK FAQ
What was Eledon Pharmaceuticals’s price range in the past 12 months?
Eledon Pharmaceuticals lowest stock price was €1.17 and its highest was €3.70 in the past 12 months.
What is Eledon Pharmaceuticals’s market cap?
Eledon Pharmaceuticals’s market cap is €226.22M.
When is Eledon Pharmaceuticals’s upcoming earnings report date?
Eledon Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were Eledon Pharmaceuticals’s earnings last quarter?
Eledon Pharmaceuticals released its earnings results on May 13, 2026. The company reported -€0.286 earnings per share for the quarter, missing the consensus estimate of -€0.16 by -€0.127.
Is Eledon Pharmaceuticals overvalued?
According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued.
Does Eledon Pharmaceuticals pay dividends?
Eledon Pharmaceuticals does not currently pay dividends.
What is Eledon Pharmaceuticals’s EPS estimate?
Eledon Pharmaceuticals’s EPS estimate is -0.14.
How many shares outstanding does Eledon Pharmaceuticals have?
Eledon Pharmaceuticals has 77,187,820 shares outstanding.
What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?
Eledon Pharmaceuticals reported an EPS of -€0.286 in its last earnings report, missing expectations of -€0.16. Following the earnings report the stock price went down -0.617%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:2TK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eledon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.23 (157.33% Upside)
€8.23 (157.33% Upside)
Blogger Sentiment
Bullish
DE:2TK Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.08%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
2TK Stock 12 Month Forecast
Average Price Target
€8.23
▲(157.33% Upside)
Technical Analysis
MacroGenics
―
Fate Therapeutics
―
ProQR
―
Bicycle Therapeutics
―
SAB Biotherapeutics
―